NLBNPIT1WV25 20240920 14 (P1WV25) News

Traders Rush To Buy Biotech Following Q1 Earnings Beat

A California-based biotech company is stealing the show so far during Tuesday’s session after the company reported Q1 2024 earnings after...

FibroGen to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

FibroGen Reports First Quarter 2024 Financial Results

Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in...

FibroGen to Report First Quarter 2024 Financial Results

SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter...

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical...

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246...

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane...

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

•  Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 •  Additional...